Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2018 2
2019 4
2020 4
2021 2
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Jackson RA, Britton RG, Jayne S, Lehmann S, Cowley CM, Trethewey CS, Smith VM, Schmid R, Fegan C, Walter HS, Dyer MJS. Jackson RA, et al. Among authors: walter hs. Blood Adv. 2023 Jul 25;7(14):3378-3381. doi: 10.1182/bloodadvances.2022009366. Blood Adv. 2023. PMID: 37257190 Free PMC article. No abstract available.
BCL2 inhibition: back to the future!
Dyer MJS, Walter HS. Dyer MJS, et al. Among authors: walter hs. Blood. 2024 May 2;143(18):1787-1788. doi: 10.1182/blood.2023023796. Blood. 2024. PMID: 38696193 No abstract available.
Chronic lymphocytic leukaemia therapy: is less more?
Walter HS, Dyer MJS. Walter HS, et al. Lancet Haematol. 2022 Mar;9(3):e169-e171. doi: 10.1016/S2352-3026(22)00044-8. Lancet Haematol. 2022. PMID: 35240069 No abstract available.
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovič M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Thompson MC, et al. Among authors: walter hs. Blood Adv. 2022 Aug 9;6(15):4553-4557. doi: 10.1182/bloodadvances.2022007812. Blood Adv. 2022. PMID: 35736670 Free PMC article. No abstract available.
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, Fegan C, Rule SA, Radford J, Cartron G, Bouabdallah K, Davies AJ, Spurgeon S, Rajakumaraswamy N, Li B, Humeniuk R, Huang X, Bhargava P, Jürgensmeier JM, Salles G. Morschhauser F, et al. Among authors: walter hs. Leukemia. 2021 Jul;35(7):2108-2113. doi: 10.1038/s41375-020-01108-x. Epub 2020 Dec 17. Leukemia. 2021. PMID: 33328591 Free PMC article. Clinical Trial. No abstract available.
New Agents to Treat Chronic Lymphocytic Leukemia.
Walter HS, Salles GA, Dyer MJ. Walter HS, et al. N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674. N Engl J Med. 2016. PMID: 27248633 Free article. No abstract available.
22 results